Cargando…

Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study

OBJECTIVES: To determine the long‐term safety of switching to brexpiprazole from aripiprazole or non‐aripiprazole dopamine antagonists. METHODS: Post‐hoc analysis of 56‐week study of Japanese outpatients with schizophrenia switched to brexpiprazole 2 mg/day over 4‐week switching period with further...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishigooka, Jun, Inada, Ken, Niidome, Kazunari, Aoki, Kazuo, Kojima, Yoshitsugu, Iwashita, Shuichi, Yamada, Sakiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365679/ https://www.ncbi.nlm.nih.gov/pubmed/33496984 http://dx.doi.org/10.1002/hup.2777

Ejemplares similares

Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
por: Inada, Ken, et al.
Publicado: (2020)

Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication)
por: Ishigooka, Jun, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2017)

Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan
por: Iwata, Nakao, et al.
Publicado: (2020)

Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective
por: Watanabe, Yoshinori, et al.
Publicado: (2020)

M191. EFFECT OF BREXPIPRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES
por: Ismail, Zahinoor, et al.
Publicado: (2020)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
por: Marder, Stephen R, et al.
Publicado: (2021)

Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study
por: Hishimoto, Akitoyo, et al.
Publicado: (2022)

Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies
por: Meade, Nicole, et al.
Publicado: (2020)

Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
por: Yokoi, Rina, et al.
Publicado: (2023)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
por: Siwek, Marcin, et al.
Publicado: (2023)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
por: Forbes, Andy, et al.
Publicado: (2018)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose, Mizue, et al.
Publicado: (2021)

The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study
por: Malla, Ashok, et al.
Publicado: (2016)

Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
por: Ivkovic, Jelena, et al.
Publicado: (2019)

A prospective naturalistic study of antidepressant-induced jitteriness/anxiety syndrome
por: Harada, Tsuyoto, et al.
Publicado: (2014)

O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
por: Hakala, Mika, et al.
Publicado: (2018)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward, Kristen, et al.
Publicado: (2019)

Analysis of the effect of brexpiprazole on sleep architecture in patients with schizophrenia: A preliminary study
por: Arai, Yusuke, et al.
Publicado: (2023)

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies
por: Correll, Christoph U., et al.
Publicado: (2016)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
por: Diefenderfer, Lauren A., et al.
Publicado: (2018)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies
por: Fava, Maurizio, et al.
Publicado: (2017)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
por: Aigbogun, Myrlene S, et al.
Publicado: (2018)

Clozapine-Treatment-Resistant Schizophrenia Successfully Managed with Brexpiprazole Combination Therapy: Two Case Reports
por: Orsolini, L., et al.
Publicado: (2022)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials
por: Zhao, Mingjun, et al.
Publicado: (2022)

Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study
por: Si, Tian Mei, et al.
Publicado: (2019)

PM384. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study
Publicado: (2016)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
por: Weiss, Catherine, et al.
Publicado: (2021)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus
por: Sakurai, Hitoshi, et al.
Publicado: (2021)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
por: Hobart, Mary, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tp77d6ulg3sb0tu8bquqqtush0